News coverage about Ekso Bionics (NASDAQ:EKSO) has been trending somewhat positive on Sunday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ekso Bionics earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned media stories about the company an impact score of 42.8125091371367 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- a bionic and tech-savy workforce manufactures a smarter, safer + healthier environment (designboom.com)
- Exoskeleton helps patients learn to walk again (wmcactionnews5.com)
- The worker in the robot suit: New industrial orders reignite exoskeleton interest (zdnet.com)
- Robotic Exoskeletons Market by 2025: Top Players Like Cyberdyne, Parker Hannifin, Panasonic Hocoma, Honda, Bionik Labs (sbwire.com)
- Ekso Bionics (EKSO) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS (americanbankingnews.com)
Several analysts have weighed in on EKSO shares. ValuEngine raised Ekso Bionics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research raised Ekso Bionics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 12th.
Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Tuesday, August 7th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Ekso Bionics had a negative net margin of 327.12% and a negative return on equity of 169.75%. The company had revenue of $2.97 million for the quarter, compared to analysts’ expectations of $3.03 million. analysts forecast that Ekso Bionics will post -0.44 earnings per share for the current fiscal year.
In other Ekso Bionics news, Director Steven Sherman acquired 200,000 shares of the business’s stock in a transaction dated Wednesday, May 23rd. The stock was purchased at an average price of $1.51 per share, with a total value of $302,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 35.45% of the company’s stock.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Further Reading: Marijuana Stocks Investing Considerations
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.